Seven Mile Advisory’s Bristol-Myers Squibb BMY Stock Holding History

Seven Mile Advisory’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,793	Closed	-$205K	–	191
2025 Q4	$205K	Buy	+3,793	New	+$182K	0.04%	241
2024 Q2	–	Sell	-4,881	Closed	-$265K	–	156
2024 Q1	$265K	Buy	4,881 +104	+2%	+$5.3K	0.2%	111
2023 Q4	$245K	Buy	4,777 +1,047	+28%	+$55K	0.21%	111
2023 Q3	$216K	Buy	3,730 +29	+0.8%	+$1.78K	0.23%	104
2023 Q2	$237K	Buy	+3,701	New	+$248K	0.28%	88

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Seven Mile Advisory's BMY Position: Q1 2026 in Review

Seven Mile Advisory sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 3,793 shares — an estimated $205K sold.

Seven Mile Advisory first reported a position in BMY in Q2 2023 and held it in 5 quarters. The position peaked at $265K in Q1 2024. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Seven Mile Advisory reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
Seven Mile Advisory sold 3,793 Bristol-Myers Squibb shares in Q1 2026, an estimated $205K.
Seven Mile Advisory first reported a position in Bristol-Myers Squibb in Q2 2023 and held it in 5 quarters.
Seven Mile Advisory's Bristol-Myers Squibb position peaked at $265K in Q1 2024.
2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Seven Mile Advisory's 13F filing for Q1 2026, filed 14 Apr 2026.